|

EBNK-001 + IL-15 + Pembrolizumab Clinical Trials

1 actively recruiting trial

Also known as: EBNK-001, IL-15, Pembrolizumab

Pipeline

Phase 1/2: 1

Top Sponsors

  • Essen Biotech1

Indications

  • Liver Disease1
  • Breast Cancer (Locally Advanced or Metastatic)1
  • Liver Cancer (Primary and Metastatic)1
  • Leukaemia1
  • Melanoma (Skin Cancer)1

Other1 trial

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.